UDP disodium salt is an endogenous agonist of P2Y receptor which preferentially activates P2Y6. It exhibis antagonistic effect on the P2Y14 receptor.

Clopidogrel Hydrogen Sulfate is the functional enantiomer of clopidogrel and a potent P2Y12 receptor antagonist.

Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

Cangrelor is a potent and competitive P2Y12 receptor inhibitor that inhibits of ADP-induced platelet aggregation.

Prasugrel HCl is a platelet inhibitor with IC50 value of 1.8 μM.

N6-(4-Hydroxybenzyl)adenosine is an inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI > 10 and with binding IC50 of 11 nM.

Clopidogrel is an inhibitor of platelet aggregation that is used to decrease the risk of myocardial infarction and stroke in patients known to have atherosclerosis. Clopidogrel has been linked to rare instances of idiosyncratic, clinically apparent acute liver injury.

Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.

MRS2578 is a potent and selective P2Y6 nucleotide receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

BPTU allosteric antagonist of P2Y1 wtih IC50 of 0.06-0.3 μM with antithrombotic effect and reduces platelet aggregation.